12 Sep 2019 | Medication Safety
This page forms part of the Appropriate prescribing toolkit. Use the links below to return to the main toolkit page or access the additional sections.
World Health Organization. 2019. Medication Safety in Polypharmacy. Geneva: World Health Organization. (WHO/UHC/SDS/2019.11). Licence: CC BY-NC-SA 3.0 IGO. Download a copy (2.7 MB, pdf)
As the population ages more people are likely to suffer from multiple long-term illness and take multiple medicines. It is therefore essential to take a person-centred approach to ensure the medicines are appropriate for the individual to gain the most benefits without any harm. This report highlights the importance of leadership in nurturing a culture that priorities safety and quality of prescribing, provides guidance on prioritising patients for medication review, the role of the patient and the importance of a multi-professional team across the health and care system, including policy makers. Included are tools and case studies that illustrate a systematic approach that can be followed by all health care professionals and the patient, across the health and care system, so patients are integral to making decisions about their medicines and feel supported to do so.
Health Quality & Safety Commission. 2019. Frailty care guides – deprescribing and polypharmacy. Wellington: Health Quality & Safety Commission. URL: www.hqsc.govt.nz/our-programmes/aged-residential-care/projects/frailty-care-guides.
Aimed at registered nurses in aged residential care, this provides guidance on deprescribing statins, proton pump inhibitors (PPIs), sedatives and hypnotics (eg, temazepam, zopiclone), antipsychotics (eg, haloperidol, risperidone) antihypertensives and anticholinergic medicines.
Scottish Government Polypharmacy Model of Care Group. 2018. Polypharmacy Guidance: Realistic Prescribing (3rd Edition). Edinburgh: NHS Scotland. Download a copy (2.8 MB, pdf)
The Scottish Polypharmacy Guidance aim is to help health care professionals to work in partnership with patients to make shared decisions that will ensure their medicines are safe and appropriate and support what matters most to them in their lives.
Polypharmacy guidance: the 7 steps. 2019. In: Polypharmacy Guidance – Medicines Review [website]. Edinburgh: NHS Scotland. URL: www.polypharmacy.scot.nhs.uk/polypharmacy-guidance-medicines-review/for-healthcareprofessionals/7-steps/.
This resource outlines a seven-step process, which provides a clear structure for both the initiation of new treatments, and the review of existing treatments.
Throughout, there is a central emphasis on ‘what matters to the patient?’ as a key driving force for decisions. The resource also provides patients and health care professionals with summary information about numbers needed to treat (NNT) for various medicines. The NNT is the average number of patients who need to be treated to prevent one additional bad outcome. This information may provide a starting point for the conversation between the health professional and patient about the likelihood of benefit from different medicines and, in some cases, the potential for other approaches such as self-management.
Available in three formats:
McCarthy D. 2017. Reducing inappropriate medication use by implementing deprescribing guidelines. Cambridge, Massachusetts: Institute for Healthcare Improvement. URL: http://www.ihi.org/resources/_layouts/download.aspx?SourceURL=%2fresources%2fKnowledge+Center+Assets%2fPublications+-+ReducingInappropriateMedicationUsebyImplementingDeprescribingGuidelines_7a4af662-5ca6-43bc-b9ac-55e5fae676fc%2fEvidenceBasedDeprescribing_InnovationCaseStudy.pdf. Download a copy (532 KB, pdf)
A multidisciplinary team of clinical experts in Ottawa, Canada, created a credible, low-cost process for developing and implementing evidence-based deprescribing guidelines and tools for assessing, tapering, and stopping medicines that may cause harm or no longer benefit patients.
Although the guidelines led primary care teams to consider approaches for identifying such medications and engaging patients in conversations about discontinuing them, the intervention has thus far been more successful in long-term care settings, where it strengthened team-based medication reviews in fulfilment of routine quality improvement and reporting requirements.
Pelton L, Knihtila M. 2018. Reducing Inappropriate Medication Use by Implementing Deprescribing Guidelines — Implementation Guide. Boston, Massachusetts: Institute for Healthcare Improvement. URL: www.ihi.org/resources/_layouts/download.aspx?SourceURL=%2fresources%2fKnowledge+Center+Assets%2fPublications+-+ReducingInappropriateMedicationUsebyImplementingDeprescribingGuidelines_7a4af662-5ca6-43bc-b9ac-55e5fae676fc%2fDeprescribing_ImplementationGuide.pdf. Download a copy (857 KB, pdf)
The implementation guide provides details on implementing the deprescribing innovation based (reference above) on the experience of US health care systems participating in the International Innovations Network Learning and Action Community, led by The Commonwealth Fund and IHI.
Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation. Making it safe and sound. The King’s Fund. London 2013. URL: www.kingsfund.org.uk/sites/default/files/field/field_publication_file/polypharmacy-and-medicines-optimisation-kingsfund-nov13.pdf. Download a copy (860 KB, pdf)
This appraises the literature on polypharmacy and medicines optimisation.
Stewart D, Mair A, Wilson M, et al and SIMPATHY consortium. 2016. Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments. Expert Opinion on Drug Safety 16(2): 203–13. URL: http://doi.org/10.1080/14740338.2017.1265503. Download a copy (845 KB, pdf)
A systematic review of the literature aiming to summarize and review critically current policies and guidelines on polypharmacy management in older people. The policy driven, evidence-based approach to managing inappropriate polypharmacy in Scotland is described, with consideration of a change management strategy based on Kotter’s eight step process for leading sustainable change.
McIntosh J, Alonso A, MacLure K, et al, on behalf of the SIMPATHY Consortium. 2018. A case study of polypharmacy management in nine European countries: Implications for change management and implementation. PLoS ONE 13(4): e0195232. URL: http://doi.org/10.1371/journal.pone.0195232. Download a copy (1.7 MB, pdf)
This provides examples of polypharmacy management initiatives that can help managers and policy makers develop new programmes or scale-up existing ones, particularly in places currently lacking such initiatives.
Managing polypharmacy and deprescribing
Managing the risks of polypharmacy in chronic disease